Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34,423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx ® in advanced breast cancer.
Li Y, Qi L, Wang Y, Li Y, Lei C, Zhang Y, Cheng X, Liu J, Bai H, Zhao X, Lv S, Xiong B, Liu J, Shi Y, Zhou H, Li H, Liu L, Jiang H, Ouyang W, Li X, Li Y, Wang X. Li Y, et al. Among authors: zhou h. Front Oncol. 2022 Dec 20;12:1070001. doi: 10.3389/fonc.2022.1070001. eCollection 2022. Front Oncol. 2022. PMID: 36605440 Free PMC article.
Evaluation of bioequivalence and safety analysis of capecitabine tablets and Xeloda® under postprandial dosing conditions in Chinese patients with solid tumor.
Li H, Shan R, Ding J, Zhang J, Liu B, Ge Q, Cheng D, Li L, Zhang C, Su H, Li X, Li H, Ye J, Li H, Li F, Zhou H, Huo Q, Su Y. Li H, et al. Among authors: zhou h. Expert Opin Drug Metab Toxicol. 2023 Dec;19(12):1015-1021. doi: 10.1080/17425255.2023.2292735. Epub 2024 Jan 12. Expert Opin Drug Metab Toxicol. 2023. PMID: 38059472 Clinical Trial.
Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B-Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein, in Healthy Chinese Subjects.
Xie J, Fan X, Su Y, Zhou H, Cao S, Zhu X, Zhu M, He C, Wang Y, Fan L, Ge Q, Zhu J, Liu B, Chen X, Xie Y, Ma L, Liu Y, Chen J, Wang H, Li Z. Xie J, et al. Among authors: zhou h. Clin Pharmacol Drug Dev. 2022 Nov;11(11):1273-1283. doi: 10.1002/cpdd.1136. Epub 2022 Jul 17. Clin Pharmacol Drug Dev. 2022. PMID: 35844038 Free PMC article. Clinical Trial.
Research progress on microRNA in gout.
Xie J, He C, Su Y, Ding Y, Zhu X, Xu Y, Ding J, Zhou H, Wang H. Xie J, et al. Among authors: zhou h. Front Pharmacol. 2022 Oct 20;13:981799. doi: 10.3389/fphar.2022.981799. eCollection 2022. Front Pharmacol. 2022. PMID: 36339582 Free PMC article. Review.
A comparative evaluation of bioequivalence of Gan & Lee glargine U300 and Toujeo® in Chinese healthy male participants.
Li X, He A, Liu B, Shan R, Zhu J, Li X, Xie T, Li Y, Chen M, Su H, Zhang C, Li L, Cheng D, Chen J, Wang Y, Su Y, Xu Y, Li Z, Zhou H, Chen W, Liu Y. Li X, et al. Among authors: zhou h. Front Endocrinol (Lausanne). 2024 Aug 7;15:1407829. doi: 10.3389/fendo.2024.1407829. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39170740 Free PMC article. Clinical Trial.
A Review of SARS-CoV2: Compared With SARS-CoV and MERS-CoV.
Zhou H, Yang J, Zhou C, Chen B, Fang H, Chen S, Zhang X, Wang L, Zhang L. Zhou H, et al. Among authors: zhou c. Front Med (Lausanne). 2021 Dec 7;8:628370. doi: 10.3389/fmed.2021.628370. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34950674 Free PMC article. Review.
34,423 results
You have reached the last available page of results. Please see the User Guide for more information.